Standard Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Standard Investments’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-17,465	Closed	-$1.96M	–	184
2014 Q3	$1.96M	Buy	+17,465	New	+$1.66M	0.1%	109

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Standard Investments's VRTX Position: Q4 2014 in Review

Standard Investments sold out of Vertex Pharmaceuticals (VRTX) in Q4 2014, closing a stake of 17,465 shares — an estimated $1.96M sold.

Standard Investments first reported a position in VRTX in Q3 2014 and held it in 1 quarter. The position peaked at $1.96M in Q3 2014. 475 funds tracked by Wall St. Rank hold VRTX as of Q4 2014.

Standard Investments reported no remaining Vertex Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Standard Investments sold 17,465 Vertex Pharmaceuticals shares in Q4 2014, an estimated $1.96M.
Standard Investments first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 1 quarter.
Standard Investments's Vertex Pharmaceuticals position peaked at $1.96M in Q3 2014.
475 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2014.

Based on Standard Investments's 13F filing for Q4 2014, filed 17 Feb 2015.